TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide found in virtually all human and animal cells. It's gained significant attention for its reported effects on tissue repair and recovery.
What Is Thymosin Beta-4?
Thymosin Beta-4 is a 43-amino-acid peptide that plays a fundamental role in cellular processes:
- Actin regulation: TB-4 is one of the main regulators of actin, critical for cell migration and wound healing
- Anti-inflammatory effects: TB-4 reduces inflammatory cytokines in multiple tissue types
- Angiogenesis: Promotes formation of new blood vessels supporting tissue repair
- Cell migration: Upregulates the ability of cells to move to injury sites
What the Research Shows
Free Resource
Get the free Peptide Starter Guide
BPC-157, Semaglutide, TB-500, GHK-Cu, Thymosin Alpha-1 — what the research says and how to source safely. Straight to your inbox.
🔒 No spam. Unsubscribe anytime.
Wound healing: Multiple animal studies demonstrate accelerated wound closure and reduced scar formation.
Cardiac repair: Animal studies show TB-4 promotes cardiac cell survival after heart attack and reduces scar tissue. A phase 2 human trial showed encouraging safety data.
Eye health: RegeneRx developed an eye drop formulation (RGN-259) for dry eye disease with positive clinical trial results.
TB-500 vs. Thymosin Beta-4
An important distinction: most published research uses Thymosin Beta-4 (the full peptide), not TB-500 (the synthetic fragment). While TB-500 contains the active region, the two are not identical. Results from TB-4 studies don't automatically apply to TB-500.
The Evidence Gaps
- Limited human data: Most research is preclinical
- WADA banned: TB-500 is banned by the World Anti-Doping Agency
- Cancer concerns: Because TB-4 promotes cell migration and angiogenesis, there are theoretical concerns with undetected cancers
Key Takeaways
TB-500 has a genuine biological basis for tissue repair. The research on Thymosin Beta-4 is promising, particularly for wound healing and cardiac repair. However, the jump from published TB-4 research to self-administered TB-500 is bigger than most sources acknowledge. Work with a knowledgeable healthcare provider.
